Key Takeaways
- • 1,135 unique healthcare deals closed in 2023 across 148 buyouts, 259 growth/expansion investments, and 728 add-on acquisitions to 422 platform companies, reflecting sustained private equity interest despite macroeconomic headwinds including high interest rates and labor shortages.
- • Quad-C Management led deal volume with 31 add-on acquisitions in 2023, while at least 22 private equity firms executed 10 or more healthcare deals, demonstrating concentrated dealmaking activity among specialized healthcare investors.
- • Outpatient care, dental, health IT, medtech, biotech, pharmaceuticals, and medical aesthetics emerged as primary investment targets, signaling PE focus on high-margin, fragmented subsectors amenable to consolidation and operational scaling.
- • Approximately 675 private equity, venture capital, and other investors participated in 2023 healthcare dealmaking, indicating broad investor appetite across the alternative asset class despite macroeconomic uncertainty.
- • PE healthcare investment raises concerns about cost-cutting impacts, with research suggesting potential negative consequences for patients and workers as PE business models prioritize outsized returns over short holding periods.
Summary
The Private Equity Stakeholder Project (PESP) released a comprehensive analysis of private equity dealmaking in U.S. healthcare throughout 2023, documenting sustained investment activity despite macroeconomic headwinds. The report, titled "Private Equity in U.S. Healthcare: Trends in 2023 Deal Activity," identified 1,135 unique transactions across the healthcare sector, underscoring private equity's continued strategic focus on an industry characterized by steady demand, demographic tailwinds from an aging population, and fragmented subsectors ripe for consolidation and operational improvement.
The deal composition reflects typical PE acquisition patterns in healthcare. The 1,135 total transactions comprised 148 buyouts of standalone healthcare businesses, 259 growth or expansion investments in existing companies, and 728 add-on acquisitions rolled into 422 unique platform companies. This structure—building platforms and layering acquisitions on top—remains a standard playbook for achieving scale and operational synergies in fragmented healthcare markets. Approximately 675 private equity, venture capital, and other alternative investors executed these transactions, indicating broad participation from the alternative asset class.
Deal volume concentrated among specialized healthcare investors. Quad-C Management led the market with 31 add-on acquisitions in 2023, while at least 22 private equity firms executed 10 or more healthcare deals during the year. This concentration suggests that healthcare expertise and sector-specific deal sourcing capabilities provide competitive advantages in identifying and executing transactions at scale.
Investment focused on high-margin, fragmented subsectors including outpatient care, dental care, health IT, and medtech, alongside emerging opportunities in biotech, pharmaceuticals, and medical aesthetics. These sectors share common characteristics attractive to PE: recurring revenue potential, multiple consolidation opportunities, and operational leverage through procurement and administrative centralization.
However, the PESP report raises material concerns regarding private equity's growing healthcare presence. The PE business model, structured around outsized financial returns achieved within defined holding periods, may incentivize cost-cutting measures that negatively impact patient outcomes and worker compensation. These considerations warrant attention from policymakers, regulators, and stakeholders monitoring healthcare access and quality as PE capital increasingly shapes the industry landscape.
The deal composition reflects typical PE acquisition patterns in healthcare. The 1,135 total transactions comprised 148 buyouts of standalone healthcare businesses, 259 growth or expansion investments in existing companies, and 728 add-on acquisitions rolled into 422 unique platform companies. This structure—building platforms and layering acquisitions on top—remains a standard playbook for achieving scale and operational synergies in fragmented healthcare markets. Approximately 675 private equity, venture capital, and other alternative investors executed these transactions, indicating broad participation from the alternative asset class.
Deal volume concentrated among specialized healthcare investors. Quad-C Management led the market with 31 add-on acquisitions in 2023, while at least 22 private equity firms executed 10 or more healthcare deals during the year. This concentration suggests that healthcare expertise and sector-specific deal sourcing capabilities provide competitive advantages in identifying and executing transactions at scale.
Investment focused on high-margin, fragmented subsectors including outpatient care, dental care, health IT, and medtech, alongside emerging opportunities in biotech, pharmaceuticals, and medical aesthetics. These sectors share common characteristics attractive to PE: recurring revenue potential, multiple consolidation opportunities, and operational leverage through procurement and administrative centralization.
However, the PESP report raises material concerns regarding private equity's growing healthcare presence. The PE business model, structured around outsized financial returns achieved within defined holding periods, may incentivize cost-cutting measures that negatively impact patient outcomes and worker compensation. These considerations warrant attention from policymakers, regulators, and stakeholders monitoring healthcare access and quality as PE capital increasingly shapes the industry landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.